Regulatory Roundup: Week of July 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: Week of July 30, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has announced rates for prescription drug user fees for fiscal year (FY) 2013, as authorized by the Prescription Drug User Fee Amendments (PDUFA V) signed into law on July 9, 2012. FDA is required to set fee revenue amounts for applications, establishments, and products each year. The FY 2013 rates, effective Oct. 1, 2012 through Sept. 30, 2013 as listed in the Federal Register, are: application fees for an application requiring clinical data, $1,958,800; an application not requiring clinical data or a supplement requiring clinical data, $979,400; establishment fees, $526,500; and product fees, $98,380. The new fee schedule applies to applications and supplements submitted on or after Oct. 1, 2012.

Cooperation and interaction between Japanese and European pharmaceutical regulators has improved since 2009, according to a report released by the European Medicines Agency (EMA). EMA reports an increase in the exchange of information and interaction between the two regions, including a new Japanese liaison officer and increased conference attendance. According to EMA, the areas of orphan drugs, pediatrics, advanced therapies, pharmacogenomics, and nanomedicines have especially benefited from the new Japan and EMA cooperation.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here